Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

2023382 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 24, Issue 12, pp. 1399-1410

Field-Weighted Citation Impact: 77.46